MicroBiome Therapeutics (MBT), a biotech firm co-founded by Whole Foods Market Chair John Elstrott, has reportedly asked consumer health care firms about developing medical foods which contain a novel ingredient that claims to improve blood glucose control and metabolic function in people deemed pre-diabetic and those diagnosed with type 2 diabetes.

According to news sources, MBT’s lead product, NM504, which contains a proprietary combination of prebiotic fiber, beta glucan and a berry extract, has been shown in rodent studies to beneficially alter the balance of gut microflora, increase insulin sensitivity, improve oral glucose tolerance test results, lower overnight fasting blood glucose levels, and improve lipid profiles. The product is currently in a clinical trial for the management of insulin sensitivity and blood glucose levels in patients with type 2 diabetes, as well as in a pilot clinical study as adjunctive therapy to the diabetes drug metformin. See CenterWatch.com, August 7, 2013; Foodnavigator-usa.com, August 12, 2013.